Purchase this article with an account.
Zeynep Bas, James Sharpe, Antonio Yaghy, Qiang (Ed) Zhang, Carol Shields, Leslie Hyman; Eyelid Cancer Prevalence and Associated Factors in the AAO IRIS® Registry. Invest. Ophthalmol. Vis. Sci. 2021;62(8):76.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To estimate prevalence of eyelid cancers in the AAO IRIS® Registry and evaluate associated factors.
All patients with ICD-9/10 codes for eyelid cancers(basal cell carcinoma [BCC],squamous cell carcinoma[SCC],malignant melanoma[MM],melanoma in-situ[MIS], sebaceous cell carcinoma/other specified malignant neoplasm[SBCC] and unspecified malignant neoplasm[UMN]),in the IRIS® registry between 12/1/2010-12/1/2018, were included. Prevalence was estimated overall, by age (categorical),race(White[W],Hispanic[H],African-American[A-A], Asian[A],Other[O],Unknown[UK]), sex (Male[M], Female[F]), and smoking status. Prevalences were compared using χ2 tests or Fisher’s exact tests. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multivariable logistic regression.
81,802 eyelid cancer patients were identified. Prevalence of Any Eyelid Cancer (AEC) was 0.14%. Tumor-specific prevalences ranged from: 0.088% (BCC), to 0.026% (UMN), 0.011% (SCC), 0.005% (SBCC), 0.004% (MM), and 0.0004% (MIS). Prevalence increased with increasing age for AEC and each tumor type (all p<0.0005), was higher in M than F for any eyelid cancer and BCC, SCC, MM (all: p<0.0001) and MIS (p=0.03), but not UMN or SBCC. Prevalence was highest in W’s compared with any other race for BCC, SCC, and SBCC (all p<0.0001). Prevalence was also higher in current/former smokers vs. non-smokers for AEC and all tumor types (all p<0.01). In the model, having AEC was associated with older ages [<20 yrs (ref.); OR (CI): 20-39 yrs: 3.6 (3.2-4.0); 40-65 yrs: 16.0 (14.7-17.6); >65 yrs: 25.6 (23.4-28.0)], M sex [F (ref.); 1.2 (1.2-1.2)], former/current smoking [never (ref.); former: 1.1 (1.1, 1.1), current: 1.2 (1.2-1.2)] and W race (inverse associations with A-A (0.1 (0.1-0.1), A (0.3 (0.3-0.3)) H (0.6 (0.5-0.6)) and O (0.6 (0.5-0.7)). Older age was associated with all tumor types, while other factors varied by type.
This is the first study to report on overall and tumor-specific prevalence of eyelid cancers from a large national clinical population. Associations with older age, male sex and white race are consistent with prior studies. The association with smoking for eyelid tumors offers guidance for disease prevention. This epidemiologic “real-world” data on eyelid cancers is valuable for risk factor assessment, planning treatment strategies, allocating medical resources, and improvements in cancer care.
This is a 2021 ARVO Annual Meeting abstract.
This PDF is available to Subscribers Only